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Abstract
Background
Evidence is growing that low-dose aspirin used as an adjuvant treatment of cancer is associ-
ated with an increased survival and a reduction in metastatic spread. We therefore extended
up to August 2017 an earlier systematic search and meta-analyses of published studies of
low-dose aspirin taken by patients with a diagnosis of cancer.
Methods
Searches were completed in Medline and Embase to August 2017 using a pre-defined
search strategy to identify reports of relevant studies. References in all the selected papers
were scanned. Two reviewers independently applied pre-determined eligibility criteria and
extracted data on cause-specific cancer deaths, overall mortality and the occurrence of met-
astatic spread. Meta-analyses were then conducted for different cancers and heterogeneity
and publication bias assessed. Sensitivity analyses and attempts to reduce heterogeneity
were conducted.
Results
Analyses of 29 studies reported since an earlier review up to April 2015 are presented in this
report, and these are then pooled with the 42 studies in our earlier publication. Overall meta-
analyses of the 71 studies are presented, based on a total of over 120 thousand patients
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taking aspirin. Ten of the studies also give evidence on the incidence of metastatic cancer
spread.
There are now twenty-nine observational studies describing colorectal cancer (CRC) and
post-diagnostic aspirin. Pooling the estimates of reduction by aspirin which are reported as
hazard ratios (HR), gives an overall HR for aspirin and CRC mortality 0.72 (95% CI 0.64–
0.80). Fourteen observational studies have reported on aspirin and breast cancer mortality
and pooling those that report the association with aspirin as a hazard ratio gives HR 0.69
(0.53–0.90). Sixteen studies report on aspirin and prostate cancer mortality and a pooled
estimate yields an HR of 0.87 (95% CI 0.73–1.05). Data from 12 reports relating to other
cancers are also listed. Ten studies give evidence of a reduction in metastatic spread; four
give a pooled HR 0.31 (95% CI 0.18, 0.54) and five studies which reported odds ratio of met-
astatic spread give OR 0.79 (0.66 to 0.95).
Conclusion
Being almost entirely from observational studies, the evidence of benefit from aspirin is lim-
ited. There is heterogeneity between studies and the results are subject to important biases,
only some of which can be identified. Nevertheless, the evidence would seem to merit wide
discussion regarding whether or not it is adequate to justify the recommendation of low-
dose therapeutic aspirin, and if it is, for which cancers?
Introduction
The role of low-dose aspirin prophylaxis is well established in vascular disease [1,2] and in the
reduction of colorectal, and probably other cancers [3–5], and it has been predicted that that
‘prevention of cancer could become the main justification for aspirin use’ [6].
The earliest reports on aspirin and cancer described a reduction in metastatic spread and
focused on the role of platelets, consistent with a treatment, rather than a preventive effect [7].
Later, evidence of effects of aspirin on certain biological mechanisms relevant to cancer growth
and to metastatic spread [8–10] justified an expectation of benefit from aspirin treatment of
cancer. Some of the long-term follow-up studies of early vascular trials gave evidence of reduc-
tions attributable to aspirin in the metastatic spread of a range of cancers in subjects who had
been free of metastases at diagnosis [11] again suggesting a treatment effect of aspirin. Further-
more, while there is usually a delay before evidence of a reduction in incident cancer becomes
apparent, a reduction in mortality appears to commence without any delay in patients who
already have metastases, again suggesting a treatment effect of aspirin [6].
On the other hand, the treatment of cancer by aspirin has been examined in only a very few
ad hoc randomised controlled trials, and these were either unrealistically small [12–14], or ran-
domisation was compromised [15]. The bulk of clinical evidence on aspirin taken by patients
with cancer is therefore limited to observational studies.
Concurrently, patients with cancer are being recruited into randomised trials of aspirin as
an adjunct treatment [16,17]. It will however be perhaps 10–15 years before evidence from
these begins to become available, and it is likely that trials will focus on only a very few of the
most common cancers. In the meantime, evidence from observational studies is, by default, of
considerable and immediate importance.
In 2016 we reported a systematic review and meta-analysis of all the reports then available
on aspirin taken by patients with cancer [18] Since then new evidence has been reported
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which we believe justifies a re-evaluation of the topic. In what follows we therefore summarise
the new evidence and we follow this with meta-analyses of all the available relevant studies. In
particular, we summarise the evidence on the three main cancers: colorectal, breast and pros-
tate, and we then list the evidence from single studies of other cancers. All this leads to a pre-
sentation of what we believe is a basic issue: whether or not the present evidence is adequate to
justify the informing of patients with cancer, and if it is adequate, then patients with which
cancers?
Methods
In 2015 we reported the results of a systematic review and meta-analysis of all available reports
published up to March 2015 [18]. We have now updated that search to August 2017 and we
present a review and meta-analysis of all the recent papers identified in a search from April
2015 to August 2017 inclusive. We then present a summary, meta-analyses and interpretation
of all the available reports on the topic.
The procedures adopted throughout followed the PRISMA guidelines [19] and a full
description of the search strategy is given in S1 File. In brief: systematic searches using key
words were conducted in Medline and Embase, limited to human studies in peer-reviewed
journals. Studies were selected by two authors (PE and GM) if (a) the studied population com-
prised patients diagnosed with cancer; (b) aspirin was taken regularly after cancer diagnosis;
(c) the studies were randomised trials, case-control studies or cohort studies. Data on cancer
specific and all-cause mortality, and data on the incidence of metastatic spread and adverse
effects attributable to aspirin were extracted. Reference lists of the relevant studies identified
were searched for relevant reports. Many of the authors were written to for additional details
and authors of all the studies were asked specifically about gastrointestinal bleeding in the
patients included in their study.
The methodological quality of the studies was assessed and graded independently by two
authors (AW and PE) using the Newcastle-Ottawa Scale [20] (see S2 File). Disagreements in
grade on a nine point scale, were discussed and agreed.
Meta-analyses were conducted, using a ’random effects’ model. Analyses were performed
first on the new papers published since April 2015, and then on all the available studies from
both the earlier search and the new search were pooled and meta-analyses performed. Egger’s
test [21] was used in looking for publication bias and funnel plots were created to highlight
outlying studies. Results of attempts to reduce heterogeneity were based on the omission of
studies which, on the tree diagrams and sensitivity analyses identified studies which were out-
lying or appeared to have an excessive influence on the pooled hazard ratios. The detailed
work on all this is given in S3 File.
Results
A literature search (April 2015 to August 2017) to up-date our earlier report [18] identified
229 new reports additional to the 640 papers we had already identified up to March 2015 [18].
Thirty-one of the 229 new reports were judged to be of relevance and on inspection of the full
text 29 fulfilled the criteria for inclusion. A summary of each of these, together with an estimate
of quality according to the Newcastle-Ottawa assessment protocol (see S2 File).
No new randomised trial was identified in the up-dating search, but there were 13 new
reports of observational studies of aspirin and colorectal cancer, four new reports in patients
with breast cancer, six of patients with prostate cancer and six of patients with other cancers.
Six reports gave evidence on metastatic spread. Details of these, including the published esti-
mates of both the cause-specific and all-cause mortality are displayed in Table 1.
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These results confirm the earlier findings we reported [18]. For colorectal cancer our earlier
review of 16 observational studies had given a pooled HR 0.71 (95% CI 0.58, 0.87) and this
more recent review gives HR = 0.68 (0.57, 0.81). Our earlier report gave a pooled estimate
based on 10 studies of breast cancer as HR = 0.68 (95% CI 0.46, 1.02), and the estimate based
on the recent reports is HR 0.70 (0.47–1.03). For prostate cancer the two estimates are not as
close, the earlier series of ten reports giving HR 0.94 (95% CI 0.76, 1.17) and the six new stud-
ies, when pooled, yield an HR of 0.74 (0.59–0.92).
These pooled results for the studies published up to March 2015 and studies published
since April 2015 are homogeneous (P<0.05) for each of the three cancers.
In our earlier report [18] we summarised the findings on aspirin and the incidence of meta-
static spread in four studies, which, when pooled gave a relative risk in patients on aspirin of
0.77 (95% CI 0.86, 0.92; heterogeneity P<0.0005). Six reports in the studies published since
March 2015 report metastatic spread, and the relationships with aspirin in these is summarised
in Table 2 (HR 0.31 (95% CI 0.18, 0.51; Heterogeneity P = 0.89).
We then proceeded to pool the results of all the available published reports, that is, both the
42 results in papers identified in our literature search to March 2015 [18] and the 29 in the
recent search April 2015 to August 2017 described above. A flow diagram is given below in S1
Fig. Tests of significance of differences in the mean estimates given for the three main cancers
in the two reviews, gave no evidence of heterogeneity (for all three: P>0.10). The review that
follows is therefore based on 71 published reports, which together describe a total of over 120
thousand patients taking aspirin.
Assessment and grading of each of the reports, using the Newcastle-Ottawa grading scheme
and including the papers which give evidence on metastatic spread, is given in S2 File.
Colorectal cancer
Only one small ad hoc randomised trial of aspirin in 66 patients with colorectal cancer appears
to have been reported. This showed an HR of 0.65 (95% CI 0.02, 18.06) for the mortality of
patients randomised to aspirin.[12] A semi-randomised study of patients with another gastro-
intestinal cancer, oesophageal cancer, reported on 445 patients admitted to two wards, in only
one of which aspirin was prescribed, showed an HR for aspirin of 0.83 (95% CI 0.68, 1.10).
[15]
A total of 29 observational studies of aspirin and colorectal cancer have been reported and
are listed in Table 1 and in our earlier report [18]. Twenty-seven give data on cause specific
mortality and in 24 the measure of association with aspirin suggests benefit, 15 significantly (at
P<0.05). In three studies [25,30,32] the measure of association exceeded 1.00 but in none of
these three is the association significant (at P<0.05).
Further analyses are limited because the reports of effects by different authors use different
indices: hazard ratios, risk ratios and odds ratios and these cannot be pooled together. How-
ever, twenty-one authors report the association with aspirin as hazard ratios, and these give a
pooled HR 0.72 (95% CI 0.64–0.81; heterogeneity 0.0005) Eggers test is significant (P = 0.02)
suggesting some publication bias. A forest plot and a funnel plot are shown in S3 File, and the
removal of one outlying study [22] which appears to have excessive influence reduces the het-
erogeneity (P<0.001) and gives HR 0.75 (95% CI 0.68–0.83). We were unable to reduce het-
erogeneity further.
Evidence of a reduction in the occurrence of metastatic spread in colorectal cancer associ-
ated with aspirin comes from three studies, two of which report ORs [48,49] and together give
0.91 (95% CI 0.65, 1.26; heterogeneity P = 0.569). Another study [26] reported a reduction in
rectal metastases in patients on aspirin as HR 0.31 (95% CI 0.18, 0.54).
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Table 1. Aspirin treatment of cancer in observational studies reported 2015–2017. For details of studies published before 2015, see our earlier report [18].
Study Aspirin/no
Aspirin
Events
aspirin/
none
Follow-up
duration
Outcome HR/RR
(95% CI)
Comment
COLORECTAL and GASTROINTESTINAL CANCER
Bains et al. [22] 6,102/17,06 0 1,158/5,375 3 years Cause specific
mortality
HR 0.85 (0.79,
0.92)
All-cause mortality HR 0.95 (0.90,
1.01)
Frows et al. [23] 1,008/8,278 5,138 Up to 15
years
Cause specific
mortality
HR 0.44 (0.33,
0.58)
Time dependent survival analyses
All-cause mortality HR 0.52 (0.44,
0.63)
Giamperie et al, [24] 20/46 8/43 6 years Progression free
survival
HR 0.48 (0.30,
0.79)
All-cause mortality HR 0.43 (0.26,
0.72)
Shimoike et al. [25] 148/343 ? Over 5 years Cause specific
mortality
HR 1.38 (0.84,
2.26)
Poster presentation. Our estimates of HR. Other
antiplatelet drugs used
All-cause mortality HR 0.61 (0.28,
1.33)
Restivo et al. [26] 37/204 ? 37months
(19-57m)
Prog free survival HR 0.20 (0.07,
0.60)
Overrall survival HR 0.21 (0.05,
0.89)
Ventura et al. [27] 9,938/ 217,070 45/742 6 years Cause specific
mortality
HR 0.71 (0.52,
0.97)
‘No certainty that aspirin taking continued to death’
All-cause mortality HR 1.18 (1.12,
1.23)
Gray et al. [28] 146/534 40/172 ? Cause specific
mortality
HR 0.69 (0.47,
0.98)
PIK3CA and PTGS2 evaluated
All-cause mortality HR 0.76 (0.57,
1.03)
Hua et al. [29] 676/1,397 17/61 11 years Cause specific
mortality
HR 0.44 (0.25,
0.71)
All-cause mortality HR 0.75 (0.59,
0.95)
Vietonmaki et al.
[30]
676/1,397 413 15 years Cause specific
mortality
HR 1.28 (0.40,
4.12)
Competing risk analyses
Murphy et al. [31] 95/296 8/43 110 months Cause specific
mortality
RR 0.72 (0.34–
1.53)
Data for mutant and wild PIK3CA combined
All-cause mortality RR 2.36 (1.44–
3.87)
Ratnsinghe et al.
[32]
5,935/3,934 44/42 Males 17–21 years M cause specific
mortality
RR 0.68 (0.37.
1.26)
8.903/4,062 71/36
Females
F cause specific
mortality
RR 1.61 (0.91,
2.85)
Hippisley-Cox et al.
[33]
4,528/39,617 ? 1–25 years Cause specific
mortality
HR 0.81 (0.73,
0.90)
Male and female data combined
All-cause mortality HR 0.85 (0.78,
0.93)
Hamada et al. [34] 269/348 37/81 11.5 years Cause specific
mortality
HR 0.65 (0.40,
1.07)
Colorectal cancer deaths: Pooled HR for eleven studies: 0.68 (0.57, 0.81), heterogeneity p<0.0005, Egger’s test for bias p = 0.09
All cause deaths: Pooled HR for nine studies: 0.76 (0.63–0.91) heterogeneity p<0.0005, Egger’s test p = 0.04
(Continued)
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Table 1. (Continued)
Study Aspirin/no
Aspirin
Events
aspirin/
none
Follow-up
duration
Outcome HR/RR
(95% CI)
Comment
BREAST CANCER
McMenamin et al.
[35]
2,822/12,318 261/929 3–6 years Cause specific
mortality
HR 0.92 (0.75,
1.14)
All-cause mortality HR 1.21 (1.04,
1.40)
Shiao et al. [36] 65/157 11/50 Up to 10
years
Cause specific
mortality
HR 0.41 (0.20,
0.83)
‘aspirin’ includes other anticoagulants
All-cause mortality HR 0.67 (0.35,
1.27)
Ratnasinghe et al.
[32]
8,903/4,062 84/47 17–21 years Cause specific
mortality
RR 0.82 (0.49,
1.36)
Two cohorts pooled
MsCarthy et al. [37] 60/52 n.a. n.a. Breast cancer
recurrence
HR 0.65 (0.46,
0.91)
Aspirin and NSAID use. Includes data on PIK3CA
Breast cancer deaths: Pooled HR for three studies: 0.70 (0.47–1.03) heterogeneity p = 0.04, Egger’s test P<0.16
All cause deaths: Pooled HR for two studies 0.98 (0.56–1.71) heterogeneity p = 0.08, Egger’s test not possible
PROSTATE CANCER
Osborrn et al. [38] 147/142 2/5 6 years Cause specific
mortality
HR 0.20 (0.04,
1.13)
Veitonmaki et al.
[39]
332/6,205 23/592 7.5 years Cause specific
mortality
HR 0.62 (0.30,
1.32)
Estimates with ‘lag time’ ignored
Zhou et al. [40] ?/? 103/67 2–7 years Cause specific
mortality
HR 0.83 (0.72,
0.95)
Results of daily aspirin in two cohorts pooled
All-cause mortality HR 0.75 (0.66,
0.86)
Cardwell et al. [41] 1,184/3,531 616/568 4–12 years Cause specific
mortality
OR 1.02 (0.78,
1.34)
All-cause mortality OR 1.22
(1.02,1.45)
Ratnasing et al. [32] 14,943/8,806 2,735/3,170 17–21 years Cause specific
mortality
RR 1.11 (0.60
2.05)
Downer et al. [42] 3,277 190/307 n.a. Cause specific
mortality
HR 0.68 (0.52,
0.90)
Long-term follow-up of a previously randomised
trial
All-cause mortality HR 0.72 (0.61,
0.84)
OTHER CANCERS
Bar et al. [43] 31/11 29/34 4 years Recurrent-free
survival
HR 0.52 (0.30,
0.90)
Ovarian 3–173 month Overall survival HR 0.50 (0.29,
0.84)
Matsuo et al. [44] 158/1,529 127 31 months Disease specific HR 0.46 (0.25,
0.86)
Endometrium. Overall survival HR 0.23 (0.08,
0.64)
Li et al. [45] 60/60
Liver
? 80 months Total mortality HR 0.60 (0.35,
1.03)
Matched pairs
Veitonmaki et al.
[30]
7,183/17,509 19/6
6/4
15 years Disease specific HR 1.27 (0.57,
2.83)
Lung
Pancreas
Disease specific HR 0.85 (0.24,
3.05)
Maddison et al. [46] 60/60 284 total ?5 years Disease specific HR 1.00
(0.73,1.37)Lung
(Continued)
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Twenty-one of the studies of colorectal cancer also report all-cause mortality. In 19 the
association with aspirin suggest a reduction with aspirin and in ten the reduction is significant.
In two studies [27,31] the association with aspirin is consistent with an excess in all-cause
deaths and in both the association is significant (at P<0.05). Eighteen studies of colorectal can-
cer report all-cause mortality as hazard ratios and pooling these gives HR 0.80 (95% CI 0.72,
0.89; heterogeneity P<0.0005; Eggers test for bias P = 0.002). The omission of three studies
[22,23,27], selected on the basis of sensitivity analyses, reduced heterogeneity (P = 0.03) and
gave HR 0.78 (95% CI 0.72, 0.85)
Overall therefore, the evidence on colorectal cancer is consistent that aspirin is associated
with a reduction in colorectal mortality and a probable reduction in the incidence of metastatic
spread. Egger’s test however suggests that there may be some publication bias in the available
data for this cancer.
Breast cancer
Our searches identified no study of aspirin randomised to patients with breast cancer. However,
14 observational studies listed in Table 1 and in our earlier report [18] have been reported, and
in eleven the association suggests benefit, significant in six studies. Three of the studies report
associations of 1.00 or greater with aspirin, but in none of these is the association significant.
Eight studies report the association with aspirin as a hazard ratio, and pooling these gives
HR 0.69 (95% CI 0.53, 0.92; heterogeneity 0.0005 and Egger’s test for bias P = 0.14). The exclu-
sion of one study [51] reduces heterogeneity (P = 0.80) and gives HR 0.80 (95% CI 0.66, 0.97)
(see S3 File).
On the occurrence of metastatic spread in breast cancer, evidence of a reduction with aspi-
rin is shown in three studies. Two [52,53] give a combined RR of 0.92 (95% CI 0.86. 0.99) and
another study [36] gives HR 0.34 (0.15, 0.81).
Table 1. (Continued)
Study Aspirin/no
Aspirin
Events
aspirin/
none
Follow-up
duration
Outcome HR/RR
(95% CI)
Comment
Kim et al. [47] Head & neck 81/1311 24–192
months
Disease specific HR 1.30 (0.78,
2.18)
Overall survival HR 1.30 (0.96,
1.92)
https://doi.org/10.1371/journal.pone.0203957.t001
Table 2. Association between aspirin taking and metastatic spread.
Author Cancer Numbers
ASA/Control
Estimates of reduction
(95% CI)
Restivo et al. [26] Rectum 37/204 HR 0.31 (0.18, 0.54)
Shiao et al. [36] Breast 65/157 HR 0.34 (0.15, 0.81)
Osborn et al. [38] Prostate 147/142 HR 0.23 (0.06, 0.91)
Rosenberg et al. [48] Colorectal 49/191 OR 0.96 (0.65, 1.40)
Sanbury et al. [49] Colorectal 75/34 OR 0.77 (0.40, 1.48)
Leitzmann et al. [50] Prostate 16/33,076 RR 0.71 (0.31, 1.62)
Pooled HR 0.31 (95% CI 0.18, 0.51) Heterogeneity P = 0.89;
Egger’s test for bias 0.138
https://doi.org/10.1371/journal.pone.0203957.t002
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Seven studies of breast cancer also reported all-cause mortality. In five the association
with aspirin suggested benefit and in three the reduction in mortality associated with aspi-
rin was significant. However, in two [36,54] the association indicated an excess in all-
cause deaths in patients on aspirin, and in one of these the excess was significant at
P<0.05. Six studies of breast cancer give a pooled estimate of all-cause mortality as HR
0.79 (95% CI 0.54, 1.16; heterogeneity p = 0.0005 and Egger’s test for bias p = 0.74). The
omission of three studies removes heterogeneity (p = 0.33) and gives HR for total mortal-
ity 0.97(95% CI 0.77, 1.21 see S3 File).
Overall therefore, there is evidence of benefit from aspirin taken by patients with breast
cancer as an adjuvant treatment in terms of a reduction in breast cancer deaths and a signifi-
cant reduction in the incidence of metastatic spread. Evidence of a reduction in all-cause mor-
tality of these patients is suggestive, but not consistent across the studies.
Prostate cancer
Our searches identified 16 observational studies, listed in Table 1 and in our earlier report.
[18] Fifteen focused on prostate cancer mortality and in ten the index of association suggested
a reduction associated with aspirin, significant in three. In five studies the measure of associa-
tion with aspirin exceeded 1.00, and in one the excess in prostate mortality with aspirin is
significant.
A pooled HR based on the thirteen studies that report the association with aspirin using
this index is 0.87 (95% CI 0.73, 1.05; heterogeneity p<0.0005 and Egger’s test P = 0.13). The
omission of one out-lying study [53] gives HR 0.84 (95% CI 0.77, 0.92; heterogeneity p = 0.17;
see S3 File).
Evidence on metastatic spread in prostate cancer associated with aspirin, comes from four
studies. Pooling three of there, gives RR 0.52 (0.39–0.68), and another study [38] gives HR 0.23
(0.06, 0.91).
Five studies on prostate cancer also reported all-cause mortality and three show a reduction
associated with aspirin, significant in two. However, in two other studies [41,55] the associa-
tion with aspirin exceeded 1.00 and was significant in both. Four studies report the association
with aspirin as hazard ratios and together these give HR 0.84 (95% CI 0.54, 1.30; heterogeneity
P<0.0005 and Egger’s test for bias P = 0.42). The omission of one outlier [55] removes hetero-
geneity and gives for all cause mortality in the prostate studies, HR 0.73 (95% CI 0.66, 0.81; see
S3 File).
The evidence on prostate cancer is therefore fairly consistent for both prostate cancer mor-
tality, and the hazard ratio for all cause mortality also suggests benefit. Correspondence with
the author of the one report that is seriously inconsistent [55] led to no clue as to why it differs
markedly from the other studies. The reduction in metastatic spread associated with aspirin is
otherwise marked and consistent. In one report [42], it is suggested that some inconsistencies
in studies of this cancer may be introduced by a selective up-take of PSA (prostate specific anti-
gen) screening, leading to bias resulting from an early diagnosis of cancer in subjects taking
aspirin.
Other cancers
Our searches identified 15 reports on aspirin and other cancers (listed in Table 1 and in our
earlier report. [18] No study showed significant evidence of detriment from aspirin specific
mortality, or all-cause mortality. There is however suggestive evidence of benefit in 10 of the
15 studies, significant in six. In addition to the reports included in Table 1 we earlier reported
evidence on ovarian cancer (HR 0.92 95% CI 0.81,1.06 [56], lung cancer (HR 0.84) [57],
Systematic review update of observational studies further supports aspirin role in cancer treatment
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bladder (OR 0.75 95% CI 0.45, 1.24) [58], a mix of women’s cancers (HR 0.82; 95% CI 0.57,
1.18) [59] and lymphocytic leukaemia (HR 0.40; 95% CI 0.21, 0.79) [60]. There have also been
two reports on head and neck cancer which differ markedly [47,61]. Associations between
aspirin and metastatic spread are shown in Table 2, and there is also an earlier report on aspi-
rin and endometrial cancer spread (HR 0.23; 05% CI 0.06, 0.91) [44].
While these single reports are a rather uncertain basis for clinical intervention, they very
strongly give encouragement for the conduct of further studies, both observational and
randomised.
All cancers
Pooling the association of aspirin with all the cancers in our reports which have been reported
as hazard ratios gives 74 (95% CI 0.66, 0.82) for cancer mortality and 0.81 (95% CI 0.73, 0.89)
for all-cause mortality. Several published reports give similar estimates for total cancer mortal-
ity. A study based on 11,001 men taking aspirin and followed for 15 years, reported an overall
reduction in all cancer deaths (HR 0.76; 95% CI 0.70, 0.82) [30]. In a report based on the US
studies NHANES I and II, Ratnasinghe et al [32] give an RR of 0.98 (95% CI 0.84, 1.14) for can-
cer mortality in 14,838 subjects taking aspirin. Elsewhere, Algra & Rothwell give pooled esti-
mates of reductions in total cancers in overviews of three previously randomised vascular trials
of aspirin (OR 0.48; 95% CI 0.30, 0.75) [3], and these authors also give an overall estimate for
the reduction in metastatic spread in long-term studies in which aspirin had originally been
randomised: OR 0.69 (95% CI 0.57, 0.83).
Pooled estimates of the reductions in metastatic spread associated with aspirin in dif-
ferent cancers are also suggestive of benefit: in our earlier report [18] estimates reported
in five studies give a pooled RR of 0.77 (95% CI 0.65, 0.92; heterogeneity P = 0.002) and
three of the studies shown in Table 2 give a pooled HR of 0.31 (95% CI 0.20, 0.48; hetero-
geneity P = 0.89).
Reports on bleeding
In our earlier review [18] we stated that four authors mentioned in their reports that no
patient had experienced a major bleeding event, and in 21 answers to an email sent to the
corresponding author of each report, none reported a major bleeding event. Again, the
recent reports since March 2017 were scanned and all the corresponding authors were
written to and asked about bleeding. The author of one report supplied data which
showed that aspirin had not been associated with any significant excess in either serious
bleeding (HR 1.11 95% CI 0.85, 1.44) or in fatal bleeding: 3% of the bleeds had been fatal
in patients taking aspirin and 3.2% had been fatal in patients not taking aspirin [27].
Another author stated that within their cohort of 120 patients with liver cancer, six
patients taking aspirin and seven not on aspirin had had a fatal gastrointestinal bleed [45].
A further author of a report with 491 patients [25] stated that a single bleeding event
occurred in a patient on antiplatelet treatment, and three events occurred in patients not
on antiplatelet treatment’. Three other authors stated than no major bleeding had
occurred in the patients they had followed.
Discussion
Ever since Gasic and colleagues reported in 1968–84 a series of pioneering studies on the role
of platelets in the metastatic spread of cancer and a reduction in the incidence of metastases
with aspirin [62–63] there has been an increasing interest in aspirin and cancer. Now, there is
extensive experimental evidence on how platelets and the coagulation system protect tumour
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cells within the circulation from immune elimination, enable cancer cells to adhere to vascular
endothelium and enhance the growth of the metastatic cells [64]. With this knowledge a reduc-
tion in metastatic spread by aspirin is a highly reasonable expectation.
The first evidence of an effect by aspirin on metastatic spread in human subjects came in
one of the long-term follow-up studies by Rothwell and colleagues [11]. Aspirin was reported
to be associated with significant reductions in metastases across a range of cancers, both in
subjects with metastases at initial diagnosis and in the risk of later metastases in patients who
had been free of metastases at diagnosis. In a later report based on long-term follow-up of par-
ticipants in 51 vascular randomised trials, Rothwell et al commented on a reduction in short-
term cancer mortality which they judged was too rapid to be attributable to ‘prevention’ and
much more likely to be a ‘treatment’ effect [6].
Cochrane and others have stressed the importance of replication in science. This paper
presents a replication of an earlier review [18] and then, because the estimates of effect of aspi-
rin are comparable in the two reviews, we have based overall conclusions on meta-analyses of
the pooled results from the two reviews. These results give extensive evidence consistent with
reductions of about 15–25% in cancer mortality by aspirin. The evidence suggests however
that there may be different levels of benefit in different cancers. Thus, there appears to be
about a 25% reduction with aspirin in the mortality of colon cancer (HR 0.75; 95% CI 0.68–
0.83), about 20% reduction in breast cancer mortality (HR 0.80; 95% CI 0.66, 0.97) and a prob-
able 15% reduction in prostate cancer deaths (HR 0.86 (95% CI 0.78, 0.95). There is also evi-
dence of a substantial reduction in the incidence of metastatic spread of these cancers, together
with a reduction in all-cause mortality across all the cancers.
Almost all the evidence we present is, however, from observational studies within which the
taking of aspirin is selective, leading to a number of important uncertainties. First, there is
marked heterogeneity between the studies and our limited success in reducing this limits con-
fidence in interpretation. There are many sources of possible differences between the series of
patients in the various studies—differences in age and social factors, differences in other treat-
ments and in general clinical management—and heterogeneity is probably inevitable, but at
the same time it seems unlikely that such differences could generate the overall benefits we
find to be associated with aspirin taking.
There are many sources of possible bias and in reviewing the present reports we were
impressed by the frequency with which authors included evidence that the patients taking aspi-
rin were older than patients not taking aspirin, and had a higher prevalence of co-morbidity,
usually because of prevalent cardiovascular disease. Both these differences will operate against
the detection of possible benefit being shown for aspirin.
In a commentary that details a number of possible sources of bias, Frouws and colleagues
comment that ‘oncologists may withhold aspirin treatment in the most seriously ill patients
because of the poor prognosis, leading to reverse causality’ [65]. We see no way to examine
this particular bias, and yet, on the other hand, if physicians had withdrawn aspirin from
patients who were seriously ill or showed marked deterioration this could have led to a
rebound in vascular deaths [66–68], and the evidence presented for all-cause mortality makes
it seem likely that if any such a process did occur, it must have been minor.
A recent paper by Rothwell et al [69] based on the long-term follow-up of five primary trials
of aspirin and vascular disease, investigated possible interactions between age/body weight/
dose of aspirin and the 20-year incidence of colon cancer. In brief, while low-dose aspirin (75–
100 mg) was associated with a significant reduction in participants who weighed less than
70Kg, significance was lost in subjects weighing 70Kg and over. With reference to aspirin and
the treatment of cancer, the report suggests ‘that low-dose aspirin might accelerate growth of
some existing cancers at lower body size, particularly at older ages.’ A number of randomised
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trials of aspirin as an adjunct treatment of cancer are in progress [16, 70–73] and these will
give opportunity to test any interactions of benefit with age, body weight and dose of aspirin.
In the meantime, observational evidence is the main basis for decisions on the use of aspirin in
cancer treatment.
Iatrogenic bleeding attributable to aspirin is clearly a most important issue. It is impor-
tant however to consider not only the frequency but also the severity of bleeding, and to
evaluate this in comparison with the likely benefits of aspirin taking, and in particular the
reduction in all-cause mortality attributable to aspirin [74]. The evidence on bleeding
summarised earlier in this report gives a measure of reassurance on bleeding and on fatal
bleeding attributable to aspirin. Elsewhere, however, [75] we have reported a careful
examination of the published evidence on fatal bleeding attributable to aspirin, showing
than the proportion of fatal bleeds which occurred in subjects randomised to aspirin is
lower that deaths due to spontaneous bleeding in subjects not on aspirin (RR 0.45; 95% CI
0.25, 0.80), and overall, in 52,583 subjects randomised to take aspirin, who together expe-
rienced 261 bleeding events, there was no significant increase in fatal bleeds in the sub-
jects on aspirin, compared to spontaneous fatal bleeds in subjects randomised not to
receive aspirin (RR 0.77; 95% CI 0.41, 1.43 P<0.91) [75]. A recent report describes
200,000 new users of low-dose aspirin, matched with a 1:1 cohort of non aspirin users
[76]. During a follow-up of 5.4 years there was an excess in total gastrointestinal bleeds
among the patients taking aspirin, but no excess in fatal bleeds (Rodrı´guez G, Lanas A,
2018. Personal communication. July, 19).
Furthermore, proton pump inhibitor drugs (PPIs) provide a high level of protection from
intestinal bleeding whatever its aetiology [77,78], and formulae to assist in judging the risk of a
gastrointestinal bleed in a subject are available [79,80].
There is also the issue of venous thromboembolism associated with cancer, and aspirin
appears to be an effective prophylactic [81,82]. Patients with malignancy appear to be in a
hypercoagulable state [83] with marked increases in both incidence and mortality of
venous thromboembolism [84,85] and The American Society of Clinical Oncology has
recommended that prophylactic anticoagulants be considered for all hospitalized cancer
patients [86].
A plea for better and more complete information on aspirin and cancer has been made
by representatives of the general public in a Citizens’ Jury held in 2006 [87] and the jurors
added to their plea the phrase: ‘even before there is agreement between doctors’. A recent
judgement by the UK Supreme Court went further and established that if a patient had
not had opportunity to review all reasonable variant treatments and to express his/her
views in a dialogue between doctor and patient, then the process of ‘informed consent’
could be called into question.[88] The court added to this judgement that if information
is material, doctors should generally disclose it and should not wait for the patient to ask.
Unfortunately however, knowledge of the likely benefit from aspirin is limited, and
apprehension about the possible side effects and attitudes towards aspirin amongst pri-
mary care physicians is likely to impede acceptance of the growing evidence of benefit.
[89]
Implications for clinical practice and for research
A number of randomised trials are in progress. It will however be some years before these
report and evidence will be limited to the more common cancers: colon [16,70–73], oesopha-
geal [16], breast [16], prostate [16,73] and lung. One trial [16] will also give evidence on aspirin
dose.
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In the meantime, observational evidence is the main basis for decisions on the use of aspirin
as an additional treatment of cancer. There is much favourable evidence on the three main
cancers, but very little on the less common cancers, though what is available is, on the whole,
encouraging. Because of the various uncertainties, the adequate informing of patients of the
benefits and the harm is difficult, but it is important that shared decision making is not com-
promised by ‘intrusive external decisions’ [90].
Every possible effort should be made to encourage observational studies. More information
is required on markers of likely benefit from aspirin such as the PIK3CA mutation, and on the
optimal dose of aspirin for treatment, taking account of age, body weight smoking and possibly
other personal factors.
Finally, valid evidence on serious and fatal bleeding attributable to aspirin, is urgently
required. An increase in bleeding with age has been well documented, but so also has an
increase in the benefits of aspirin and the balance between these outcomes needs to be evalu-
ated in different groups of subjects and patients.
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